CSL Acquires Majority Interest in Chinese Plasma Business

By

King of Prussia’s biotherapeutics company CSL Behring to acquire clinical-stage biotechnology company Calimmune for $91 million.

Australia’s CSL Limited along with its CSL Behring business unit in King of Prussia has acquired a majority stake in Chinese plasma company Wuhan Zhong Yuan Rui De Biological Products, writes John George for Philadelphia Business Journal.

CSL bought the 80 percent stake from Humanwell Healthcare Group, to secure a strategic presence in the Chinese domestic plasma fractionation market. It also complements the leadership position that CSL Behring has built over the last two decades exporting the liver protein Albumin to China.

“We will contribute our extensive plasma manufacturing expertise with a goal to expand and grow plasma collection capabilities and introduce new products into this high-growth market,” said Paul Perrault, CEO of CSL.

He added that in cooperation with Humanwell , the company intends to work closely both with local regulators and the sector to improve safety and quality of plasma, and to enhance the plasma donor experience.

The deal, which is subject to regulatory approval and Humanwell shareholders, should be completed later this year.

Read more about the acquisition at Philadelphia Business Journal by clicking here.

[uam_ad id=”52088″]

Stay Connected, Stay Informed

Subscribe for great stories in your community!

"*" indicates required fields

Hidden
MT Yes
This field is for validation purposes and should be left unchanged.
Advertisement